A New Oral Pill Just Beat Oral Ozempic in a Head to Head Trial
Oral semaglutide, sold as Rybelsus, has had the oral GLP1 space mostly to itself for a while. That just changed. A new head to head trial gives Eli Lilly's orforglipron, its own once daily pill, a real claim to being the stronger option, at least on the numbers, and at least so far.
- A 52 week phase 3 trial of 1,698 adults with type 2 diabetes found Eli Lilly's once daily pill orforglipron beat oral semaglutide (Rybelsus) on both blood sugar control and weight loss.
- Orforglipron cut HbA1c by 1.71 to 1.91 points versus 1.47 points for oral semaglutide, and produced more weight loss, 6.1 to 8.2 kg versus 5.3 kg.
- It's a small molecule, not a peptide, which could make it cheaper to manufacture, needing no refrigeration, and skipping the empty stomach ritual oral semaglutide requires.
- The tradeoff: more GI side effects (59% versus 37 to 45%) and a higher dropout rate (10% versus 4 to 5%).
An oral dose. The whole point of the head-to-head is that both drugs are swallowed, and one of them is a small molecule rather than a peptide.
Shixart1985CC BY 2.0
Illustrative. A generic blister pack, not orforglipron or oral semaglutide.
What the researchers actually did
The trial, called ACHIEVE 3, followed 1,698 adults with type 2 diabetes across six countries for 52 weeks, comparing orforglipron head to head against oral semaglutide. It's the first direct trial pitting the two oral GLP1 drugs against each other, published in The Lancet and reported independently by an academic at the University of Surrey not affiliated with Lilly.
What the evidence actually shows
From a starting average HbA1c of 8.3%, orforglipron brought it down by 1.71 to 1.91 percentage points over the year, compared with 1.47 points for oral semaglutide. It also produced more weight loss, 6.1 to 8.2 kg versus 5.3 kg. Orforglipron met its goal of performing at least as well as oral semaglutide, then beat it outright on both measures. The catch is tolerability: 59% of people on orforglipron had GI side effects versus 37 to 45% on oral semaglutide, and 10% dropped out compared with 4 to 5%, likely because orforglipron produces sharper daily peaks in drug concentration.
HbA1c points, orforglipron
Against 1.47 points for oral semaglutide, from a starting average of 8.3%.
Kilograms lost, orforglipron
Against 5.3 kg for oral semaglutide over the same 52 weeks.
Had GI side effects
Against 37 to 45% on oral semaglutide. 10% dropped out, against 4 to 5%.
One industry-sponsored trial, in adults with type 2 diabetes only, not the weight-loss population most of the current interest is coming from. No head to head against injectable GLP1s exists yet.
Honest caveat
This is one industry sponsored trial, funded and run by Eli Lilly, the maker of orforglipron, and it hasn't been independently replicated yet. It was also conducted only in adults with type 2 diabetes, not the broader weight loss only population most of the current orforglipron interest is coming from, those trials are still ongoing. There's no head to head trial yet against injectable GLP1s either. None of this means the numbers are wrong, but a single company funded trial in one population is a real limit worth knowing before treating this as settled.
Orforglipron. A small molecule, not a peptide, which is the reason a pill can work at all.
MeodiptWikimedia CommonsPublic domain
A structural diagram, not a photograph of a tablet.
What this means for you
the real decision may come down to tolerability rather than raw efficacy
If you're already choosing between GLP1 pills, or waiting to see what becomes available, this trial suggests the real decision may come down to tolerability rather than raw efficacy, since orforglipron's edge in blood sugar and weight loss comes with a real bump in GI side effects and people dropping out. It's also a genuinely practical shift if orforglipron eventually reaches the market broadly: as a small molecule rather than a peptide, it could end up cheaper and easier to distribute, including in places without reliable refrigeration.
Primary sources
- Phase 3 trial, The Lancet, 2026. Peer reviewed randomized controlled trial, industry sponsored by Eli Lilly.
- ScienceDaily, "Oral GLP1 pill orforglipron outperforms oral semaglutide in head to head diabetes trial," July 8, 2026. Independent secondary reporting by Martin Whyte, University of Surrey.
Common questions
Is orforglipron available yet?
Not yet. This trial was run in adults with type 2 diabetes, and separate trials testing orforglipron purely for weight loss are still ongoing. It has not been approved by the FDA for either use as of this writing.
Is orforglipron actually better than oral semaglutide?
On the numbers in this one trial, yes, it lowered blood sugar and produced more weight loss. But it also came with more GI side effects and a higher dropout rate, so it is a real tradeoff rather than a clean win, and tolerability may end up mattering more to most people than the efficacy edge.
Is orforglipron a peptide like semaglutide?
No, and that is one of the more practically interesting parts of this story. Orforglipron is a small molecule rather than a peptide, which means it is cheaper to manufacture, does not need refrigeration, and skips the empty stomach, thirty minute wait ritual that oral semaglutide requires.
Stay Curious.
Better health isn't found in a single article. It's built through curiosity, evidence, and small discoveries over time. Join thousands exploring longevity, gut health, recovery, nutrition, and the tools that truly make a difference.